Staff Reports
The Pentagon’s new push to test troops for low testosterone is sold as a readiness move. But Secretary Pete Hegseth’s plan raises more questions than answers. The memo orders annual screening for service members 30 and older, yet the department hasn’t said how much this will cost, how it will be measured, or even which lab cutoffs it will use. For a policy that covers a big chunk of the force, that is not reassuring — it’s reckless management dressed up as medicine.
What Secretary Hegseth actually ordered
In a short public announcement and a July memo, Secretary Pete Hegseth directed the department to add testosterone testing to routine health checks for troops age 30 and up. The stated goal is to find hormone problems, build a baseline, and offer treatment to those diagnosed. Hegseth stressed the program is “not about artificial enhancement” and framed it as part of warfighter performance and resilience. That sounds fine in theory. In practice, the memo gives services a month to write rules and gives taxpayers zero dollars or details to hold anyone accountable.
Big questions the Pentagon still won’t answer
We deserve straight answers. How many service members will be tested? What laboratory standards and confirmatory tests will be used? Will positive screens be checked twice before any therapy starts? Will the cost be paid from existing health budgets or will Congress be asked for new money? None of that has been laid out. Skipping those basics is a recipe for waste, confusion, and worse — overtreatment based on a single lab draw and an arbitrary age cutoff.
Medical sense — and who benefits?
Experts say routine population screening for low testosterone in healthy, asymptomatic men lacks solid evidence. The term “Operator Syndrome,” which the department cites, comes from work with special-operations troops who were already seeking care. That is not the same as testing millions of healthy service members and handing out therapy like a bandage. A higher lab cutoff will label more men as “low” and could push unnecessary prescriptions. We should be improving sleep, pain care, and traumatic brain injury treatment first — not launching a mass drug program with an unknown price tag.
Politics, parity, and the missing price tag
This announcement also opens awkward political knots. The department has strict rules on some hormone treatments for transgender troops. Yet it now plans a large screening and possible therapy rollout for tens of thousands of men — and the department won’t say whether women will get equivalent attention for menopause or hormonal disorders. That smells like policy by press release. And the budget silence is dangerous. If this costs hundreds of millions and leads to more long-term prescriptions, taxpayers and Congress should get a say before the first vial is ordered.
Bottom line: readiness needs answers, not headlines
We all want a strong, healthy military. But strength comes from clear thinking, evidence, and tight stewardship of dollars and lives. Secretary Hegseth should be applauded for focusing on troop health. He should be criticized — loudly — for announcing a major medical program without basic details on cost, confirmatory testing, gender parity, and outcome measures. Before the department turns this into a full-scale policy, Congress and military doctors need to demand the data. Troops deserve protection from sloppy policy, not the next shiny fad in the name of readiness.
